Phase 2 Lupus Trial, Recruiting NCT03673748 Sponsor: Red de Terapia Celular Condition: Lupus
Back to Lupus

Phase 2 Lupus Trial, Recruiting

NCT03673748
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older and are willing to sign a consent form to take part.
  • You have been diagnosed with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues, confirmed by meeting standard medical criteria.
  • You have been diagnosed with lupus nephritis (a type of kidney disease caused by lupus), confirmed by a kidney biopsy taken within the last 6 months (or up to 1 year if you are joining due to a flare-up).
  • Your lupus kidney disease has not fully responded to standard treatment, or you are experiencing a moderate to severe flare-up.
  • Your lupus disease activity score (called SLEDAI-2K) is 10 or higher, meaning your lupus is currently quite active (confirm with trial site).
  • If you are a woman who could become pregnant, you must be using an effective form of birth control during the trial.
  • You have received vaccines against pneumonia and flu as part of standard vaccination programmes.

Who may not be able to join:

  • You have been taking corticosteroids (steroid medicines) or mycophenolate at doses higher than those allowed under specific Spanish medical guidelines (confirm with trial site).
  • You have received certain biologic medicines targeting immune cells, such as rituximab, belimumab, or ocrelizumab, in the 6 months before joining.
  • You have been treated with cyclophosphamide (a strong immune-suppressing medicine) in the 6 months before joining.
  • You have used medicines called TNF inhibitors (a type of immune-suppressing drug) in the 6 months before joining.
  • You have received intravenous immunoglobulin therapy in the 6 months before joining.
  • Your dose of certain blood pressure medicines (ACE inhibitors or angiotensin receptor blockers) has been changed in the 2 months before joining.
  • You have taken part in another clinical trial or taken an experimental medicine within 3 months before joining (or within a specific time based on the medicine used).
  • You have another serious uncontrolled health condition that the trial doctors feel makes participation unsafe or could affect the trial results.
  • You have had a heart attack, stroke, or serious blood vessel event in the 6 months before joining.
  • You have an active heart rhythm problem or a significant abnormality on a heart tracing (ECG) that the doctors consider unsafe.
  • You have had a blood clot in the 12 months before joining, or your blood-thinning treatment is not at the right level.
  • You have severe or worsening lupus affecting your brain or nervous system, such as recent uncontrolled seizures or significant memory/thinking problems.
  • You have a history of, or currently have, a nerve-damaging condition such as multiple sclerosis or optic neuritis.
  • You have another condition, such as asthma or inflammatory bowel disease, that requires you to take steroid medicines regularly.
  • You have had an organ transplant in the past or have one planned.
  • You currently have a significant infection, have recently been hospitalised for an infection, or have a history of getting the same type of infection three or more times in a 12-month period (minor infections such as oral or genital herpes, vaginal thrush, or nail fungus would not necessarily exclude you — confirm with trial site).
  • You have tested positive for HIV, hepatitis B, or hepatitis C.
  • You have active or latent tuberculosis (TB), unless you have already completed or are well into an adequate course of TB treatment.
  • You have severe, uncontrolled heart failure.
  • You currently have active cancer.
  • You have had major surgery within 6 weeks before joining, or have major surgery planned during the trial period.
  • You are pregnant or breastfeeding.
  • You have significant abnormal blood or lab test results that are not explained by your lupus.
  • A recent chest X-ray shows signs of active tuberculosis.
  • You have been legally declared unable to make decisions for yourself.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Julia Barbado, MD, PhD, University Hospital Río Hortega, Valladolid, Spain

Phone: +34 983 420400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Red de Terapia Celular
Registry
ClinicalTrials.gov
Start date
27 December 2022
Est. completion
1 December 2026

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Proportion of patients who have achieved complete response; Proportion of patients who have achieved partial response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov